| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research & development | 3,755,335 | 2,499,498 | ||
| General & administrative | 3,124,260 | 2,339,230 | ||
| Loss from operations | -6,879,595 | -4,838,728 | ||
| Interest income | 65 | 64 | ||
| Interest expense | - | 0 | ||
| Change in fair value of warrant liability | - | -302,042 | ||
| Total other income/expense | 65 | 302,106 | ||
| Net loss | -6,879,530 | -4,536,622 | ||
| Cumulative series a preferred stock dividend requirement | - | 0 | ||
| Net loss available to common shareholders | -6,879,530 | -4,536,622 | ||
| Basic loss per common share outstanding (in dollars per share) | -0.21 | -0.19 | ||
| Diluted loss per common share outstanding (in dollars per share) | -0.21 | -0.19 | ||
| Weighted average of shares (in shares) | 31,956,686 | 25,114,460 | ||
OS Therapies Inc (OSTX)
OS Therapies Inc (OSTX)